LOXL1 and cancer: However, this protective physiological process is dysregulated in cancer where TAFs retain their activated state and produce excessive amounts of collagen along with the collagen crosslinking enzymes like lysyl oxidase (LOX) and lysyl oxidase-like 1 (LOXL1), which increase ECM stiffness and direct tumour progression.